Jean-Paul Renaud
Overview
Explore the profile of Jean-Paul Renaud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haas N, Thompson J, Renaud J, Chennen K, Poch O
Database (Oxford)
. 2024 Oct;
2024.
PMID: 39395187
Nonsense variations, characterized by premature termination codons, play a major role in human genetic diseases as well as in cancer susceptibility. Despite their high prevalence, effective therapeutic strategies targeting premature...
2.
Renaud J, Chari A, Ciferri C, Liu W, Remigy H, Stark H, et al.
Nat Rev Drug Discov
. 2018 Jun;
17(7):471-492.
PMID: 29880918
Cryo-electron microscopy (cryo-EM) of non-crystalline single particles is a biophysical technique that can be used to determine the structure of biological macromolecules and assemblies. Historically, its potential for application in...
3.
Renaud J, Chung C, Danielson U, Egner U, Hennig M, Hubbard R, et al.
Nat Rev Drug Discov
. 2016 Aug;
15(10):679-98.
PMID: 27516170
Over the past 25 years, biophysical technologies such as X-ray crystallography, nuclear magnetic resonance spectroscopy, surface plasmon resonance spectroscopy and isothermal titration calorimetry have become key components of drug discovery...
4.
Schiebel J, Radeva N, Koster H, Metz A, Krotzky T, Kuhnert M, et al.
ChemMedChem
. 2015 Aug;
10(9):1511-21.
PMID: 26259992
Fragment-based lead discovery is gaining momentum in drug development. Typically, a hierarchical cascade of several screening techniques is consulted to identify fragment hits which are then analyzed by crystallography. Because...
5.
Marek M, Kannan S, Hauser A, Mourao M, Caby S, Cura V, et al.
PLoS Pathog
. 2013 Oct;
9(9):e1003645.
PMID: 24086136
The treatment of schistosomiasis, a disease caused by blood flukes parasites of the Schistosoma genus, depends on the intensive use of a single drug, praziquantel, which increases the likelihood of...
6.
Hoffer L, Renaud J, Horvath D
J Chem Inf Model
. 2013 Mar;
53(4):836-51.
PMID: 23537132
This paper describes the use and validation of S4MPLE in Fragment-Based Drug Design (FBDD)--a strategy to build drug-like ligands starting from small compounds called fragments. S4MPLE is a conformational sampling...
7.
Ferry G, Studeny A, Bossard C, Kubara P, Zeyer D, Renaud J, et al.
Life Sci
. 2011 Jul;
89(7-8):259-68.
PMID: 21736880
Aims: We have developed biochemical and cell based assays to characterize small therapeutic molecules that inhibit the DNA damage checkpoint enzyme, Chk1 (Checkpoint kinase 1). Main Methods: To prepare a...
8.
Hoffer L, Renaud J, Horvath D
Comb Chem High Throughput Screen
. 2011 Apr;
14(6):500-20.
PMID: 21521152
Fragment-based screening is an emerging technology which is used as an alternative to high-throughput screening (HTS), and often in parallel. Fragment screening focuses on very small compounds. Because of their...
9.
Renaud J, Delsuc M
Curr Opin Pharmacol
. 2009 Jul;
9(5):622-8.
PMID: 19581126
Biophysical methods are currently involved in drug design in two ways: the qualitative detection of small molecule binding to a target (hit identification), and the quantitative determination of physical parameters...
10.
Paris M, Escriva H, Schubert M, Brunet F, Brtko J, Ciesielski F, et al.
Curr Biol
. 2008 Jun;
18(11):825-30.
PMID: 18514519
Most studies in evolution are centered on how homologous genes, structures, and/or processes appeared and diverged. Although historical homology is well defined as a concept, in practice its establishment can...